Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density

Menopause International

Volumn 15, Issue 3, 2009, Pages 100-106

  Benster, Beverly ^a   Carey, Adam ^a   Wadsworth, Fred ^a   Griffin, Maura ^b   Nicolaides, Andrew ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

atherosclerosis; bone density; menopause; plaque; Progesterone cream; ultrasound

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; PROGESTERONE;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE DENSITY; CAROTID ARTERY BIFURCATION; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEMORAL ARTERY; FEMUR NECK; HUMAN; INTRAVASCULAR ULTRASOUND; LUMBAR SPINE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; AGED; ATHEROSCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OINTMENTS; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; PROGESTERONE; TREATMENT OUTCOME;

EID: 69949156812     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2009.009017     Document Type: Article

References (37)

1. Lee JR. Natural Progesterone the Multiple Roles of a Remarkable Hormone. 2nd edn. England: John Carpenter Publishing, 1999
2. Lee JR. Is natural progesterone the missing link in osteoporosis prevention and treatment? Med Hypotheses 1991; 35: 316–318
3. Lee JR. Use of Pro-Gest cream in postmenopausal women. Lancet 1998; 352: 905; author reply 906
4. Lee JR. Topical progesterone. Menopause 2003; 10: 374–377; author reply 377–379
5. Lee JR. What Your Doctor May Not Tell You About Menopause: The Breakthrough Book on Natural Progesterone. New York: Warner Books, 1996
6. Mac Namara P, Loughrey HC. Progesterone receptor A and B isoform expression in human osteoblasts. Calcif Tissue Int 1998; 63: 39–46
7. Tremollieres FA, Strong DD, Baylink DJ, Mohan S. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenhagen) 1992; 126: 329–37
8. Tertinegg L, Heersche JN. Progesterone stimulates bone nodule formation in rat cadavarial cell cultures while oestrogen has no effect. J Bone Miner Res 1993; 7: S220
9. Barengolts EI, Gajardo HF, Rosol TJ,, et al. Effects of progesterone on postovariectomy bone loss in aged rats. J Bone Miner Res 1990; 5: 1143–7
10. Lindsay R, Hart DM, Purdie D,, et al. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978; 54: 193–195
11. Abdalla HI, Hart DM, Lindsay R,, et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66: 789–92
12. Morey AK, Pedram A, Razandi M,, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 1997; 138: 3330–9
13. Lee WS, Harder JA, Yoshizumi M,, et al. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 1997; 3: 1005–8
14. Jiang CW, Sarrel PM, Lindsay DC,, et al. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol 1992; 211: 163–167
15. Minshall RD, Stanczyk FZ, Miyagawa K,, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab 1998; 83: 649–59
16. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327
17. Barrett-Connor E, Slone S, Greendale G,, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27: 261–74
18. Rylance PB, Brincat M, Lafferty K,, et al. Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 1985; 290: 13–14
19. Stevenson JC, Purdie DW. Use of Pro-Gest cream in postmenopausal women. Lancet 1998; 352: 905–906;
20. Wren BG. Progesterone creams: do they work? Climacteric 2003; 6: 184–187
21. Carey BJ, Carey AH, Patel S,, et al. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. BJOG 2000; 107: 722–726
22. Cooper A, Spencer C, Whitehead MI,, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998; 351: 1255–6
23. Mircioiu C, Perju A, Griu E,, et al. Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. Eur J Drug Metab Pharmacokinet 1998; 23: 397–402
24. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2002; 41: 1–6
25. Wren BG, Champion SM, Willetts K,, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003; 10: 13–18
26. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94: 225–228
27. Furberg CD, Adams HP Jr, Applegate WB,, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679–87
28. Espeland MA, Applegate W, Furberg CD,, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol 1995; 142: 1011–9
29. Akkad A, Hartshorne T, Bell PR, al-Azzawi F. Carotid plaque regression on oestrogen replacement: a pilot study. Eur J Vasc Endovasc Surg 1996; 11: 347–348
30. Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester: John Wiley and Sons Ltd, 2006
31. Vashisht A, Wadsworth F, Carey A,, et al. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol 2005; 21: 101–105
32. Wren BG, McFarland K, Edwards L,, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000; 3: 155–60
33. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999; 180 (6 Pt 1): 1504–11
34. Byington RP, Furberg CD, Herrington DM,, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002; 22: 1692–7
35. Hodis HN, Mack WJ, Lobo RA,, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939–53
36. Angerer P, Stork S, Kothny W,, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 262–268
37. Bots ML, Evans GW, Riley W,, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006; 27: 746–55